Insuline Medical Ltd. is a Public Israeli company (TASE – INSL) focused on improving the performance of current insulin treatment methods, by trying to better approximate human physiology.
Even with today’s rapid acting insulin analogs, there is a gap of at least one hour between bolus insulin injection and its peak in the blood system.
Our solutions are disposable devices which treat with heat the point of injection, in order to improve and stabilize blood perfusion. It can be integrated into catheters used with insulin pumps, or as a stand alone disposable compatible with syringe or pen delivery.
We have clinical evidence showing that our device improves post-parandial glucose levels in controlled environment and daily life. Our technology improves rapid acting analogues by the same order of magnitude that they improved on regular insulin.
The technology, while seemingly straight forward requires balancing blood perfusion effectiveness while also avoiding overheating the insulin itself above the allowed threshold. It is protected by pending patents globally, and involves significant device knowhow.
We have CE mark for our products and we are building independent go-to-market ability in Germany first, to be expanded later on, to Europe and the US.
We have recently launched studies as part of our FDA submission, according to the agreed upon 510k framework. Results are expected by the summer.
In preparation for launching the injection product in Germany we have hired key executive, have formed a fully owned subsidiary (InsuLine-Medical GmbH), and are gearing up towards manufacturing and pre-marketing studies. We are getting positive confirmations from leading sick funds regarding reimbursement.
We are building independent go-to-market ability in Germany first, to be expanded later on, to Europe and the US.
We are open to possible collaboration with insulin and device players for distribution, joint trials, and bundling opportunities.
